UKKW Expert panel: Real-World Evidence
Overview
Dr Lisa Willcocks outlines a practical approach to managing IgA nephropathy, focusing on sparsentan and using real-world case studies to illustrate diagnosis, treatment, and disease progression.
Download the certificate here once you have completed this webinar
Prescribing information and adverse event reporting information:
Filspari®▼(sparsentan): 200 mg , 400 mg
UK-SPT-2500152 (V2.0) | September 2025
Adverse events should be reported. Reporting forms and information for the United Kingdom can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Fresenius Medical Care Renal Pharma, care of Vifor Pharma Ltd.
Tel: +44 1276 853633. E-mail: MedicalInfo_UK@viforpharma.com.
